全文获取类型
收费全文 | 2100篇 |
免费 | 95篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 134篇 |
妇产科学 | 86篇 |
基础医学 | 147篇 |
口腔科学 | 60篇 |
临床医学 | 157篇 |
内科学 | 448篇 |
皮肤病学 | 52篇 |
神经病学 | 116篇 |
特种医学 | 97篇 |
外科学 | 534篇 |
综合类 | 27篇 |
预防医学 | 45篇 |
眼科学 | 68篇 |
药学 | 78篇 |
中国医学 | 3篇 |
肿瘤学 | 98篇 |
出版年
2024年 | 1篇 |
2023年 | 11篇 |
2022年 | 19篇 |
2021年 | 63篇 |
2020年 | 56篇 |
2019年 | 49篇 |
2018年 | 57篇 |
2017年 | 52篇 |
2016年 | 66篇 |
2015年 | 80篇 |
2014年 | 84篇 |
2013年 | 101篇 |
2012年 | 127篇 |
2011年 | 138篇 |
2010年 | 112篇 |
2009年 | 65篇 |
2008年 | 150篇 |
2007年 | 155篇 |
2006年 | 154篇 |
2005年 | 156篇 |
2004年 | 123篇 |
2003年 | 98篇 |
2002年 | 83篇 |
2001年 | 52篇 |
2000年 | 38篇 |
1999年 | 23篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 3篇 |
1995年 | 3篇 |
1994年 | 12篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 11篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 7篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1909年 | 1篇 |
排序方式: 共有2205条查询结果,搜索用时 15 毫秒
51.
Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus
下载免费PDF全文
![点击此处可从《BJU international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
52.
Synthesis and biological evaluation of phloroglucinol derivatives possessing α‐glycosidase,acetylcholinesterase, butyrylcholinesterase,carbonic anhydrase inhibitory activity
下载免费PDF全文
![点击此处可从《Archiv der Pharmazie》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Serdar Burmaoglu Ali O. Yilmaz Parham Taslimi Oztekin Algul Deryanur Kilic Ilhami Gulcin 《Archiv der Pharmazie》2018,351(2)
53.
Harun Cakmak Esra Gokmen Gokay Bozkurt Tolga Kocaturk Kemal Ergin 《Cutaneous and ocular toxicology》2018,37(2):191-195
Aim: To evaluate the effects of sunitinib (0.5?mg/ml) and bevacizumab (5?mg/ml) on VEGF-A, VEGFR-2 and microRNA (miRNA) levels on corneal neovascularization (CNV).Methods: In this study, CNV was induced by silver nitrate application to the cornea, and 40 Albino male rats were equally divided into four subgroups:Group 1 (sunitinib): After silver nitrate application to the cornea, 0.5?mg/ml sunitinib eyedrop was administered twice daily for two weeks (n?=?10).Group 2 (bevacizumab): After silver nitrate application to the cornea, 5?mg/ml bevacizumab eyedrop was administered twice daily for two weeks (n?=?10).Group 3 (control): After silver nitrate application to the cornea, normal saline eyedrop was administered twice daily for two weeks (n?=?10).Group 4 (vehicle): After silver nitrate application to the cornea, 1% DMSO eyedrop was administered twice daily for two weeks (n?=?10).After two weeks from the silver nitrate application, corneas were evaluated by hand-held biomicroscope for their vascularization status. Then, corneas were excised and the expression levels of VEGFR-2, VEGF-A and the common miRNA markers for neovascularization (miR-15?b, miR-16, miR-23a, miR-126, miR-188, miR-210, miR-221, miR-222, miR-410 and miR-423) were evaluated by real-time PCR.Results: It was seen that the CNV was decreased in sunitinib- and bevacizumab-administered groups compared to the control and DMSO groups. Also, in comparison with the control group; VEGF-A expression was downregulated by nearly 0.75 times in sunitinib group and nearly 0.52 times in bevacizumab group. VEGFR-2 expression was downregulated by 0.89 times in sunitinib group and 0.68 times in bevacizumab group, compared to the control group. miR-15?b, miR-16 and miR-126 levels were statistically lower in sunitinib and bevacizumab groups, but miR-188 and miR-410 levels were two-fold higher compared to the control group. The miR-210 level was found higher only in sunitinib group compared to the control group. There were no statistically significant changes in miR-23a, miR-221, miR-222 and miR-423 levels among the groups.Conclusion: Topical application of bevacizumab (5?mg/ml) and sunitinib (0.5?mg/ml) decreases the levels of VEGFR-2 and VEGF-A in CNV. Further studies are needed for detailed analysis of genes which are targeted by up- or downregulated miRNAs in this study. 相似文献
54.
55.
56.
57.
58.
James A. Brown MA George J. Arnaoutakis MD Arman Kilic MD Thomas G. Gleason MD Edgar Aranda-Michel BS Ibrahim Sultan MD 《Journal of cardiac surgery》2020,35(9):2331-2337
Within the spectrum of acute aortic syndromes, intramural hematoma (IMH) is a distinct lesion that is characterized by crescentic or circumferential thickening of the aortic wall in the absence of an intimal defect. The reported incidence of IMH among all type A acute aortic syndromes ranges from 3.5% to 28.3%. As compared with acute aortic dissection, IMH is a disease of the elderly, and it tends to have reduced rates of malperfusion syndromes, aortic insufficiency, and root dilation, yet also tends to have increased rates of pericardial effusion, cardiac tamponade, and periaortic hematoma. With respect to natural history, IMH may progress to classic dissection, frank rupture, or aneurysmal dilation; yet, IMH may also regress and be completely resorbed. However, studies disagree over the rates of progression or regression; as such, few studies agree on the short-term and long-term prognosis associated with IMH. American and European guidelines advocate emergent surgery for all acutely presenting type A IMH. At a minimum, supracoronary replacement of the aorta with hemiarch reconstruction is the preferred extent of operative repair to reduce rates of long-term reintervention for disease progression. However, valve and/or root procedures may be necessary proximally, while total arch reconstruction or hybrid procedures for the descending aorta may be necessary distally. Much remains unknown for IMH, including the ideal extent of aortic repair, risk-stratification for elderly patients, and the optimal treatment paradigm for stable, uncomplicated IMH. As such, IMH remains a diagnostic and therapeutic challenge for the cardiovascular surgeon. 相似文献
59.